Lifecore Biomedical vs Rockwell Medical
LFCR and RMTI side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How LFCR and RMTI compare
Lifecore Biomedical is the larger company, worth 8.6 times as much as Rockwell Medical ($243M against $28.3M).
Lifecore Biomedical grew revenue faster over the last twelve months (0.47% versus −4.0% for Rockwell Medical).
Rockwell Medical keeps more of each dollar of sales as profit, with a net margin of −7.8% compared with −30.0% at Lifecore Biomedical.
Rockwell Medical scores higher on the StockData Score (11 against 4 for Lifecore Biomedical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | LFCR | RMTI |
|---|---|---|
| Size and price | ||
| Market cap | $243M | $28.3M |
| Share price | $6.42 | $7.03 |
| Change, 1 year | −21.9% | −26.4% |
| Change, 5 years | −32.3% | −86.7% |
| Beta (5Y) | 1.04 | 1.80 |
| Employees | 382 | 157 |
| StockData Score | ||
| Total score | 4 | 11 (better) |
| Valuation score | 1 | 3 (better) |
| Growth score | 0 | 1 (better) |
| Performance score | 2 | 3 (better) |
| Health score | 1 | 4 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 1.9× | 0.4× (better) |
| P/B | – | 0.9× |
| P/FCF | – | 34.2× |
| FCF yield | −5.6% | 2.9% (better) |
| Fair value | – | $32.08 |
| Margin of safety | – | 78.1% |
| Growth | ||
| Revenue growth (TTM) | 0.47% (better) | −4.0% |
| Revenue growth, 5Y average | −4.2% | 2.2% (better) |
| Net income growth (TTM) | −422% | – |
| EPS growth (TTM) | −485% | – |
| Profitability | ||
| Gross margin | 31.3% (better) | 18.1% |
| Operating margin | −13.4% | −7.1% (better) |
| Net margin | −30.0% | −7.8% (better) |
| FCF margin | −10.6% | 1.1% (better) |
| Return on equity | – | −16.1% |
| Return on invested capital | – | −19.5% |
| Financial health | ||
| Debt / equity | – | 0.27 |
| Interest coverage | −0.8× (better) | −4.6× |
| Current ratio | 3.84 (better) | 2.47 |
| Altman Z-score | −0.52 (better) | −7.86 |
| Piotroski F-score | 5 (better) | 2 |
| Dividends and buybacks | ||
| Buyback yield | −9.8% | – |
| Shareholder yield | −9.8% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 67.1% | 0.05% |
| Held by insiders | 46.1% | 100% |
| Insider net buying, 12 months | – | −$11.6K |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 8.4% | – |
Go deeper
- LFCR stock overview
- LFCR income statement
- LFCR valuation and score
- RMTI stock overview
- RMTI income statement
- RMTI valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.